Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 15, Issue 3, 2019
http://www.tandfonline.com/toc/khvi20/current

Article
Global impact of varicella vaccination programs
Fernanda Hammes Varela, Leonardo Araújo Pinto & Marcelo Comerlato Scotta
Pages: 645-657
Published online: 10 Dec 2018

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 15, Issue 3, 2019
http://www.tandfonline.com/toc/khvi20/current

Article
Knowledge, attitudes, behaviours, and beliefs of healthcare provider students regarding mandatory influenza vaccination
Heba Ghandora, Donna M. Halperin, Jennifer E. Isenor, Beth A. Taylor, Philippe Fullsack, Antonia M. Di Castri & Scott A. Halperin
Pages: 700-709
Published online: 04 Jan 2019

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 15, Issue 3, 2019
http://www.tandfonline.com/toc/khvi20/current

Article
Experience implementing a university-based mass immunization program in response to a meningococcal B outbreak
Blair Capitano, Krista Dillon, Andre LeDuc, Bruce Atkinson & Cynthia Burman
Pages: 717-724
Published online: 08 Jan 2019

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 15, Issue 3, 2019
http://www.tandfonline.com/toc/khvi20/current

Article
Impact of a vaccination promotion intervention using motivational interview techniques on long-term vaccine coverage: the PromoVac strategy
Thomas Lemaitre, Nathalie Carrier, Anne Farrands, Virginie Gosselin, Geneviève Petit & Arnaud Gagneur
Pages: 732-739
Published online: 04 Jan 2019

International Journal of Epidemiology
Volume 48, Issue 1, February 2019
https://academic.oup.com/ije/issue/48/1

Opinion
Precision public health—the Emperor’s new clothes
David Taylor-Robinson; Frank Kee
International Journal of Epidemiology, Volume 48, Issue 1, February 2019, Pages 1–6, https://doi.org/10.1093/ije/dyy184
Extract
Recently the Centre for Disease Control suggested that ‘precision public health’ presents significant opportunities to improve the health of the population,1 but what does this concept add and does it live up to the hype? The promise is that by harnessing the power of Big Data, particularly genomic data, we may indeed see early gains in public health as a result of ‘more-accurate methods for measuring disease, pathogens, exposures, behaviors, and susceptibility’ to guide targeted prevention strategies.2 However, the term ‘precision public health’ is susceptible to misinterpretation.

JAMA
April 2, 2019, Vol 321, No. 13, Pages 1229-1320
http://jama.jamanetwork.com/issue.aspx

Viewpoint
Current and Future Challenges for Children Across the World
Zulfiqar A. Bhutta, MBBS, FRCPCH, PhD; Robert E. Black, MD, MPH
free access
JAMA. 2019;321(13):1251-1252. doi:10.1001/jama.2019.1840
This Viewpoint argues that children have been left behind in UN and other global health efforts, calls for a focus on health measures beyond survival to define success, and outlines requirements to achieve real improvements in child health, including access to preventive care, a focus on education and nutrition, and introduction of information systems to monitor the population effects of health services.

[See Milestones above for full text]

JAMA Pediatrics
April 2019, Vol 173, No. 4, Pages 303-404
http://archpedi.jamanetwork.com/issue.aspx

Viewpoint
Challenges in Early Childhood Development
Kemin Qi, MD
JAMA Pediatr. 2019;173(4):307-308. doi:10.1001/jamapediatrics.2018.5381
This Viewpoint describes the significance of early childhood development (ECD) and the global challenges many clinicans face and proposes approaches and objectives for governments to reach to scale up ECD.

JAMA Pediatrics
April 2019, Vol 173, No. 4, Pages 303-404
http://archpedi.jamanetwork.com/issue.aspx

Original Investigation
Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children
Naïm Ouldali, MD; Corinne Levy, MD; Philippe Minodier, MD; et al.
JAMA Pediatr. 2019;173(4):362-370. doi:10.1001/jamapediatrics.2018.5273
This time-series analysis of community-acquired pneumonia diagnosed in 8 pediatric emergency departments in France assesses the rate of infection in children 15 years and younger before and after implement of a 13-valent pneumococcal conjugate vaccine.

Journal of Travel Medicine
Volume 26, Issue 1, 2019
https://academic.oup.com/jtm/issue/26/1

Perspectives
Human mobility and health in a warming world
Patricia Nayna Schwerdtle, MPH, RN; Kathryn Bowen, PhD, MSc; Celia McMichael, PhD, MSc; Rainer Sauerborn, MD, PhD, MPH, MSc
Journal of Travel Medicine, Volume 26, Issue 1, 2019, tay160, https://doi.org/10.1093/jtm/tay160
Climate change will shape patterns of human mobility on a spectrum of voluntary migration to forced displacement. This paper discusses the nexus between climate change, migration and health, identifies climate hotspots and explores the health implications for climate-related migration.

Journal of Travel Medicine
Volume 26, Issue 1, 2019
https://academic.oup.com/jtm/issue/26/1

Massive diphtheria outbreak among Rohingya refugees: lessons learnt
Md Ridwanur Rahman, MBBS, FCPS; Khaleda Islam, MBBS, MPH
Journal of Travel Medicine, Volume 26, Issue 1, 2019, tay122, https://doi.org/10.1093/jtm/tay122
Several lessons can be learnt from the massive diphtheria outbreak faced by Rohingya (forcibly displaced Myanmar nationals) refugees who fled violence in Myanmar and settled in camps and makeshift settlements in Cox’s Bazar, Bangladesh, 2017–2018.

The Lancet
Apr 06, 2019   Volume 393Number 10179p1385-1476, e36
https://www.thelancet.com/journals/lancet/issue/current

Editorial
China’s research renaissance
The Lancet
   … An outward-looking China could broaden the influence of its scientific renaissance by fostering synergy between health researchers at home and abroad. In this way, the country’s research impact would be maximised. When researchers across countries embrace a collegial approach, advances in care anywhere are more likely to improve outcomes everywhere.

Nature 
Volume 568 Issue 7750, 4 April 2019
http://www.nature.com/nature/current_issue.html

Editorial | 02 April 2019
Court ruling highlights the threat of vaccine misinformation
Distorted facts that undermine uptake of the human papillomavirus vaccine could leave a generation at risk.
[See Milestones above for full text]

Nature Medicine
Volume 25 Issue 4, April 2019
https://www.nature.com/nm/volumes/25/issues/4

Review Article | 01 April 2019
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
Broadly neutralizing antibodies have the potential to clear HIV and prevent further infection, as shown in emerging clinical studies.
Marina Caskey, Florian Klein & Michel C. Nussenzweig

New England Journal of Medicine
April 4, 2019   Vol. 380 No. 14
http://www.nejm.org/toc/nejm/medical-journal

Perspective
Pharmacologic Research in Pregnant Women — Time to Get It Right
Ahizechukwu C. Eke, M.D., M.P.H.,
Kelly E. Dooley, M.D., Ph.D.,
and Jeanne S. Sheffield, M.D.
Facilitating inclusion of pregnant women in clinical research could help answer important questions about the effects of medication use during pregnancy and the ways in which pregnancy alters pharmacokinetics and drug effects.

New England Journal of Medicine
April 4, 2019   Vol. 380 No. 14
http://www.nejm.org/toc/nejm/medical-journal

Perspective
An Epidemic of Suspicion — Ebola and Violence in the DRC
Vinh-Kim Nguyen, M.D.
[Excerpts]
… As a medical team leader for Médecins sans Frontières (MSF), I work halfway between Butembo and Goma, North Kivu’s capital city and a transport hub.
…The community outreach workers I supervise have reported that in areas where security forces accompany Ebola teams, there is substantial distrust and palpable fear, most notably of forced vaccination. In areas where the epidemic response has not involved security forces, the opposite is true: people ask to be vaccinated. The lesson is clear: guns and public health don’t mix. Epidemics thrive on fear — when they are frightened, patients flee hospitals, sick people stay away to begin with, and affected communities distrust groups trying to respond to the epidemic.
As they see Land Rovers emblazoned with the logos of nongovernmental and international organizations cruising by, people in the DRC say, “Ebola is just a business.” They note that no one seems to care about daily deaths from malaria and other infectious diseases, the lack of clean water, or surgeries that must be performed by candlelight because there’s no power. “You will leave when Ebola does,” I have heard, “but we will still be here, slowly dying from the diseases that have always killed us.”…
…The mistrust of authority in the DRC also reflects a growing global mistrust of experts and science. Vaccine refusals are a growing problem worldwide, and they have already resulted in measles epidemics in the United States and France and in outbreaks elsewhere. Mistrust of public health authorities may thus be the new norm, and smoldering epidemics merely a symptom. State-of-the-art medical interventions won’t be enough without serious efforts to rebuild trust, informed by social science rather than pious liturgies. Displays of armed force feed a vicious cycle of mistrust, infection, and violence. If we continue down that path, those seemingly fantastical dystopian outbreak movies, with their heavily armed global health forces and rebelling populations, may not be so far from reality in the near future.

Pediatrics
April 2019, VOLUME 143 / ISSUE 4
https://pediatrics.aappublications.org/content/143/4?current-issue=y

Pediatrics Perspectives
How to Prepare for Expert Testimony on the Safety of Vaccination
Stanley A. Plotkin
Pediatrics Apr 2019, 143 (4) e20183578; DOI: 10.1542/peds.2018-3578

Pharmaceutics
Volume 11, Issue 3 (March 2019)
https://www.mdpi.com/1999-4923/11/3

Open Access  Review
The Digital Pharmacies Era: How 3D Printing Technology Using Fused Deposition Modeling Can Become a Reality
by Maisa R. P. Araújo, Livia L. Sa-Barreto, Tais Gratieri, Guilherme M. Gelfuso and Marcilio Cunha-Filho
Pharmaceutics 2019, 11(3), 128; https://doi.org/10.3390/pharmaceutics11030128
Received: 24 February 2019 / Revised: 12 March 2019 / Accepted: 14 March 2019 / Published: 19 March 2019
Abstract
The pharmaceutical industry is set to join the fourth industrial revolution with the 3D printing of medicines. The application of 3D printers in compounding pharmacies will turn them into digital pharmacies, wrapping up the telemedicine care cycle and definitively modifying the pharmacotherapeutic treatment of patients. Fused deposition modeling 3D printing technology melts extruded drug-loaded filaments into any dosage form; and allows the obtainment of flexible dosages with different shapes, multiple active pharmaceutical ingredients and modulated drug release kinetics—in other words, offering customized medicine. This work aimed to present an update on this technology, discussing its challenges. The co-participation of the pharmaceutical industry and compounding pharmacies seems to be the best way to turn this technology into reality. The pharmaceutical industry can produce drug-loaded filaments on a large scale with the necessary quality and safety guarantees; while digital pharmacies can transform the filaments into personalized medicine according to specific prescriptions. For this to occur, adaptations in commercial 3D printers will need to meet health requirements for drug products preparation, and it will be necessary to make advances in regulatory gaps and discussions on patent protection. Thus, despite the conservatism of the sector, 3D drug printing has the potential to become the biggest technological leap ever seen in the pharmaceutical segment, and according to the most optimistic prognostics, it will soon be within reach.

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 6 Apr 2019)

Policy Forum
A whole-health–economy approach to antimicrobial stewardship: Analysis of current models and future direction
Monsey McLeod, Raheelah Ahmad, Nada Atef Shebl, Christianne Micallef, Fiona Sim, Alison Holmes
Policy Forum | published 29 Mar 2019 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002774

PLoS One
http://www.plosone.org/
[Accessed 6 Apr 2019]

Research Article
Hepatitis B vaccination status and associated factors among undergraduate students of Makerere University College of Health Sciences
Yvette Wibabara, Cecily Banura, Joan Kalyango, Charles Karamagi, Alex Kityamuwesi, Winfred Christine Amia, Ponsiano Ocama
Research Article | published 05 Apr 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0214732

PLoS One
http://www.plosone.org/
[Accessed 6 Apr 2019]

Factors contributing to racial disparities in influenza vaccinations
Suma Vupputuri, Kevin B. Rubenstein, Alphonse J. Derus, Bernadette C. Loftus, Michael A. Horberg
Research Article | published 03 Apr 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0213972

Qualitative Health Research
Volume 29 Issue 5, April 2019
http://qhr.sagepub.com/content/current

Special Issue: Qualitative Contributions to Randomized Control Trials
Guest Editorial
Evaluating Complex Health Interventions With Randomized Controlled Trials: How Do We Improve the Use of Qualitative Methods?
Jenevieve Mannell, Katy Davis
First Published March 14, 2019; pp. 623–631
Preview
Qualitative methods are underutilized in health intervention evaluation, and overshadowed by the importance placed on randomized controlled trials (RCTs). This Commentary describes how innovative qualitative methods are being used as part of RCTs, drawing on articles included in a special issue of Qualitative Health Research on this topic. The articles’ insights and a review of innovative qualitative methods described in trial protocols highlights a lack of attention to structural inequalities as a causal mechanism for understanding human behavior. We situate this gap within some well-known constraints of RCT methodologies, and a discussion of alternative RCT approaches that hold promise for bringing qualitative methods center stage in intervention evaluation, including adaptive designs, pragmatic trials, and realist RCTs. To address the power hierarchies of health evaluation research, however, we argue that a fundamental shift needs to take place away from a focus on RCTs and toward studies of health interventions.

Qualitative Health Research
Volume 29 Issue 5, April 2019
http://qhr.sagepub.com/content/current
Special Issue: Qualitative Contributions to Randomized Control Trials

Special Issue Articles
Parental Experiences of Child Participation in a Phase I Pediatric Oncology Clinical Trial: “We Don’t Have Time to Waste”
Stacey Crane, Joan E. Haase, Susan E. Hickman
First Published April 11, 2018; pp. 632–644
Abstract
Children with cancer are only eligible for phase I clinical trials (P1Ts) when no known curative therapy remains. However, the primary aims of P1Ts are not focused on directly benefiting participants. This raises ethical concerns that can be best evaluated by exploring the experiences of participants. An empirical phenomenology study, using an adapted Colaizzi method, was conducted of 11 parents’ lived experiences of their child’s participation in a pediatric oncology P1T. Study findings were that parents’ experiences reflected what it meant to have a child fighting to survive high-risk cancer. Although elements specific to P1T participation were identified, more pervasive was parents’ sense of running out of time to find an effective treatment and needing to use time they had with their child well. Even though some problems were identified, overall parents did not regret their child’s P1T participation and would recommend P1Ts to other parents of children with cancer.

Research Ethics
Volume 15 Issue 2, April 2019
http://journals.sagepub.com/toc/reab/current

Topic Piece
The attitude of scholars has not changed towards plagiarism since the medieval period: Definition of plagiarism according to Shams-e-Qays, thirteenth-century Persian literary scientist
Ramin Sadeghi
First Published May 31, 2016; pp. 1–3
Abstract
Almost all researchers are familiar with the concept of plagiarism these days. However, many scholars allege that plagiarism and its ethical ramifications are new western concepts that have not existed in scientific and literary history. In their opinion, using the ideas of others was allowed liberally in past academic and literary communities. I have presented the definition of “plagiarism” according to Shams-e-Qays, a great Persian literary scientist of the thirteenth century AD, to show that this is not the case and that the attitude towards plagiarism was even more strict in ancient times.

Research Ethics
Volume 15 Issue 2, April 2019
http://journals.sagepub.com/toc/reab/current

Original Article: Empirical
Status of retraction notices for biomedical publications associated with research misconduct
Daniel Drimer-Batca, Jonathan M Iaccarino, Alan Fine
First Published January 2, 2019; pp. 1–5

Risk Analysis          
Volume 39, Issue 4  Pages: 741-956  April 2019
https://onlinelibrary.wiley.com/toc/15396924/current

Original Research Article
Reaping the Benefits and Avoiding the Risks: Unrealistic Optimism in the Health Domain
Yaniv Hanoch, Jonathan Rolison, Alexandra M. Freund
Pages: 792-804
First Published: 04 October 2018
Abstract
People’s perceptions of benefits and risks play a key role in their acceptance or rejection of medical interventions, yet these perceptions may be poorly calibrated. This online study with N = 373 adults aged 19–76 years focused on unrealistic optimism in the health domain. Participants indicated how likely they were to experience benefits and risks associated with medical conditions and completed objective and subjective numeracy scales. Participants exhibited optimistic views about the likelihood of experiencing the benefits and the side effects of treatment options described in the scenarios. Objective and subjective numeracy were not associated with more accurate ratings. Moreover, participants’ underestimation of the risks was significantly greater than their overestimation of the benefits. From an applied perspective, these results suggest that clinicians may need to ensure that patients do not underestimate risks of medical interventions, and that they convey realistic expectations about the benefits that can be obtained with certain procedures.

Science         
05 April 2019  Vol 364, Issue 6435
http://www.sciencemag.org/current.dtl

Review
The challenge of antimicrobial resistance: What economics can contribute
By Laurence S. J. Roope, Richard D. Smith, Koen B. Pouwels, James Buchanan, Lucy Abel, Peter Eibich, Christopher C. Butler, Pui San Tan, A. Sarah Walker, Julie V. Robotham, Sarah Wordsworth
Science05 Apr 2019
Incentivizing restraint in drug use
The accelerating tide of antimicrobial resistance (AMR) is a major worldwide policy concern. Like climate change, the incentives for individual decision-makers do not take into account the costs to society at large. AMR represents an impending “tragedy of the commons,” and there is an immediate need for collective action to prevent future harm. Roope et al. review the issues associated with AMR from an economics perspective and draw parallels with climate change. A major stumbling block for both challenges is to build consensus about the best way forward when faced with many uncertainties and inequities.

Abstract
As antibiotic consumption grows, bacteria are becoming increasingly resistant to treatment. Antibiotic resistance undermines much of modern health care, which relies on access to effective antibiotics to prevent and treat infections associated with routine medical procedures. The resulting challenges have much in common with those posed by climate change, which economists have responded to with research that has informed and shaped public policy. Drawing on economic concepts such as externalities and the principal–agent relationship, we suggest how economics can help to solve the challenges arising from increasing resistance to antibiotics. We discuss solutions to the key economic issues, from incentivizing the development of effective new antibiotics to improving antibiotic stewardship through financial mechanisms and regulation.

Travel Medicine and Infectious Diseases
Volume 28  Pages 1-120 (March–April 2019)
http://www.travelmedicinejournal.com/

Editorial  No access
Shortage of yellow fever vaccination: A travel medicine emergency for Chilean travellers
Thomas Weitzel, Pablo Vial, Cecilia Perret, Ximena Aguilera
Pages 1-2

Travel Medicine and Infectious Diseases
Volume 28  Pages 1-120 (March–April 2019)
http://www.travelmedicinejournal.com/

Editorial  No access
Intradermal travel vaccinations-when less means more
Frieder Schaumburg, Cornelis A. De Pijper, Martin P. Grobusch
Pages 3-5

Travel Medicine and Infectious Diseases
Volume 28  Pages 1-120 (March–April 2019)
http://www.travelmedicinejournal.com/

Review article  Abstract only
Clinical respiratory infections and pneumonia during the Hajj pilgrimage: A systematic review
Samir Benkouiten, Jaffar A. Al-Tawfiq, Ziad A. Memish, Ali Albarrak, Philippe Gautret
Pages 15-26

Travel Medicine and Infectious Diseases
Volume 28  Pages 1-120 (March–April 2019)
http://www.travelmedicinejournal.com/

Review article  Abstract only
From the “Madding Crowd” to mass gatherings-religion, sport, culture and public health
Qanta A. Ahmed, Ziad A. Memish
Pages 91-97

Vaccine
Volume 37, Issue 16 Pages 2167-2284 (10 April 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/16

Discussion  No access
Effective and equitable influenza vaccine coverage in older and vulnerable adults: The need for evidence-based innovation and transformation
Gregory A. Poland, Laura Lee Hall, Jennifer A. Powell, for the Advisory Group Meeting “Influenza Immunization among Older Adults: Population Health Strategies for Promoting Equity and Achieving Healthy People 2020 Goals ”
Pages 2167-2170

Vaccine
Volume 37, Issue 16 Pages 2167-2284 (10 April 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/16

Short communication  Abstract only
Ebola epidemic in war-torn Democratic Republic of Congo, 2018: Acceptability and patient satisfaction of the recombinant Vesicular Stomatitis Virus – Zaire Ebolavirus Vaccine
Masumbuko Claude Kasereka, Julia Sawatzky, Michael T. Hawkes
Pages 2174-2178

Vaccine
Volume 37, Issue 16 Pages 2167-2284 (10 April 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/16

Research article  Abstract only
Comparison of early childhood vaccination coverage and timeliness between children born to Italian women and those born to foreign women residing in Italy: A multi-centre retrospective cohort study
Massimo Fabiani, Valeria Fano, Teresa Spadea, Cinzia Piovesan, … Patrizio Pezzotti
Pages 2179-2187

Vaccine
Volume 37, Issue 16 Pages 2167-2284 (10 April 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/16

Research article  Full text access
It’s not all about autism: The emerging landscape of anti-vaccination sentiment on Facebook
Beth L. Hoffman, Elizabeth M. Felter, Kar-Hai Chu, Ariel Shensa, … Brian A. Primack
Pages 2216-2223

Vaccine
Volume 37, Issue 16 Pages 2167-2284 (10 April 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/16

Research article  Abstract only
Caregiver’s attitudes, beliefs, and experiences for influenza vaccination in Australian children with medical comorbidities
Daniel A. Norman, Margie Danchin, Paul Van Buynder, Hannah C. Moore, … Holly Seale
Pages 2244-2248

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

[No new digest content identified]

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
 
 
The Atlantic
http://www.theatlantic.com/magazine/
Accessed 6 Apr 2019
[No new, unique, relevant content]
 
 
BBC
http://www.bbc.co.uk/
Accessed 6 Apr 2019
Published Date
4 Apr 2019
HPV vaccine linked to ‘dramatic’ drop in cervical disease
…The routine vaccination of girls with the HPV vaccine in Scotland…
 
 
Devex
https://www.devex.com/news
Accessed 6 Apr 2019
Global Views / Global health
Opinion: It’s time to rebuild public confidence in vaccines
By Heidi Larson // 03 April 2019
…However, the answer to combating today’s currents of vaccine dissent is far more complex than addressing the needed technical fixes and must be part of a wider effort involving multiple partners, including citizens. If the moves of tech companies are perceived as censorship, they may only harden the views of those who feel they already have no voice…
 
 
The Economist
http://www.economist.com/
Accessed 6 Apr 2019
[No new, unique, relevant content]
 
 
Financial Times
http://www.ft.com/home/uk
Accessed 6 Apr 2019
[No new, unique, relevant content]
 
 
Forbes
http://www.forbes.com/
Accessed 6 Apr 2019
[No new, unique, relevant content]
 
 
Foreign Affairs
http://www.foreignaffairs.com/
Accessed 6 Apr 2019
[No new, unique, relevant content]
 
 
Foreign Policy
http://foreignpolicy.com/
Accessed 6 Apr 2019
[No new, unique, relevant content]
 
 
The Guardian
http://www.guardiannews.com/
Accessed 6 Apr 2019
Vaccines and immunisation
‘Sentencing their dog to death’: how the anti-vax movement spread to pets
There has been a spike in people refusing to vaccinate pets against deadly diseases, including some that can infect humans
Michael McGowan
Sat 6 Apr 2019 00.52 EDT
 
 
New Yorker
http://www.newyorker.com/
Accessed 6 Apr 2019
[No new, unique, relevant content]
 
 
New York Times
http://www.nytimes.com/
Accessed 6 Apr 2019
Opinion
Parenting in the Time of Measles
As many as half of the home-schooled kids I encounter are not vaccinated.
By Bethany Mandel
Ms. Mandel, who home-schools her children, is a part-time editor at Ricochet.
April 3, 2019

Health
Scientists Thought They Had Measles Cornered. They Were Wrong.
Following intensive vaccination efforts, measles cases plunged across the world. Now clusters of new infections — some linked, some not — have confounded health officials.
April 3, 2019

U.S.
Kentucky Judge Rules Against Unvaccinated Student in Lawsuit
A Kentucky judge has ruled against a student who sued after he wasn’t allowed to play basketball because he wasn’t vaccinated for chickenpox.
April 2, 2019

Scientific American
https://www.scientificamerican.com/
Accessed 6 Apr 2019
April 2019
How the World’s First Dengue Vaccination Drive Ended in Disaster –
Is a runaway immune reaction making a dengue vaccine dangerous?

Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 6 Apr 2019
Letters
Dealing With Measles Vaccination Deniers
23 hours ago
Perhaps if we stop worrying about our political agendas and concentrate on the health of our children, we will no longer read headlines about children needlessly being infected with preventable illnesses…

Washington Post
http://www.washingtonpost.com/
Vaccine wars: Social media battle outbreak of bogus claims
Barbara Ortutay | AP · Business · Apr 5, 2019

Think Tanks et al

Brookings
http://www.brookings.edu/
Accessed 6 Apr 2019
[No new relevant content]

Center for Global Development  
http://www.cgdev.org/page/press-center
4/3/19
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? It Depends
Publication
Is price transparency really the answer to healthcare systems’ fiscal sustainability challenges as they strive to expand access to new technologies or even merely sustain provision within strained public budgets? Well, it depends!
Pdf: https://www.cgdev.org/sites/default/files/can-transparency-lower-prices-and-improve-access-pharmaceuticals-it-depends.pdf

CSIS
https://www.csis.org/
Accessed 6 Apr 2019
[No new relevant content]

Council on Foreign Relations
http://www.cfr.org/
Accessed 6 Apr 2019
April 4, 2019
Mozambique
Cyclone Idai Reveals Africa’s Vulnerabilities
Floodwaters in Mozambique could spread cholera, raising the death toll even after the storm has passed.
by Laura Hillard

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 6 Apr 2019
[No new relevant content]

Milestones :: Perspectives

WHO – SAGE [Strategic Advisory Group of Experts] Meeting
The next SAGE meeting will take place in Geneva from the 2-4 April 2019.
Draft agenda for SAGE April 2019 meeting  pdf, 76kb  [As of 25 March 2019]

Selected Agenda Items
:: Quality and Use of Immunization and Surveillance Data
:: Report from the Global Advisory Committee on Vaccine Safety (GACVS) meeting 5-6 December 2018
:: Update on the development of a Post-2020 Immunization Strategy
:: Malaria Vaccine
:: Polio the last mile
:: Meningococcal vaccines: Global Strategy
:: Ebola vaccines
:: Update on the SAGE Evaluation

Milestones :: Perspectives

Polio Eradication

Dr Tedros Adhanom Ghebreyesus, WHO Director-General and Chair of the Polio Oversight Board, issued a personal response [first text below] to the joint statement published in January by the Chairs of the main, independent, advisory and oversight committees of the GPEI [second text below].

March 2019
Dear Chairs of the GCC, IHR Emergency Committee, 1MB and SAGE,
On behalf of the Global Polio Eradication Initiative (OPEi) and as current Chair of the Polio Oversight Board, I would like to thank you for your recently-published joint communique on the polio eradication effort. Your assessment of the current global situation, and what needs to happen to achieve success, is as accurate as it is motivating. Thank you for this strong call for action.

Let me assure you: all partners of the OPEi fully agree with you.

As a global community, we have been engaged in this fight for 31 years now. Wild poliovirus cases now persist in only a handful of districts of just two countries – Pakistan and Afghanistan.

In January, I was joined by Dr Al Mandhari, Regional Director for the Eastern Mediterranean, and Dr Chris Elias, President of the Global Development Division at the Bill & Melinda Gates Foundation, as we visited both countries where we witnessed first-hand the tremendous efforts being undertaken to interrupt the remaining chains of wild polio transmission there. I have rarely been so impressed by public health efforts being undertaken as in these two areas, as both countries work hand-in-hand to tackle this joint epidemiological block, as both countries engage and mobilise all levels of public and civil society to support this effort.

As you rightly point out, eradication is an “all-or-nothing” approach. We either eradicate, or we do not. And the truth is, everything in place for success to be achieved. The Endgame Plan through 2013-2018 has brought us to the brink of being polio-free. And the Strategic Plan 2019-2023 aims to build on the lessons learned since 2013. Its aim is to increase performance everywhere, including using the proven tools of eradication and building blocks that have been established, while using opportunities to innovate using local knowledge and insights to overcome obstacles that in the past have seemed insurmountable. The key is to optimise all these approaches, and if the Plan is fully financed and implemented at all levels, a lasting polio-free world will be secured for all future generations to come.

That is why I commit to you today: we will rise to your call to action, and we will excel in our jobs, and this will lead to the success we all want to see. As you challenge us, we commit to making it our overriding objective to find and reach that last unvaccinated child before the poliovirus does. We will give the poliovirus nowhere to hide.

Your continued guidance, independent assessments and oversight will be critical to help us in securing this success. It is this guidance which has been instrumental in helping bring us to the threshold of a polio-free world, and it will be your continued guidance which will help us finally cross this threshold. Please continue with your assessments. Continue to critically evaluate what we are doing. Continue to issue your joint statements to draw attention to what needs to be done. We must have this oversight.

On behalf of our partners at Rotary International, the US Centers for Disease Control and Prevention (CDC), UNICEF, the Bill & Melinda Gates Foundation, and mostly on behalf of the children of the world, thank you!

Dr Tedros Ghebreyesus
Director-General, World Health Organization
Chair, Polio Oversight Board of the Global Polio Eradication Initiative

::::::

January 2019
Dear Polio Eradicator,

The global polio eradication effort is 31 years old.

The world is tantalizingly close to being free of polio. From 350,000 wild poliovirus cases every year in 1988, in 2018 the world reported just 29 cases of this devastating disabling disease because of extraordinary global efforts. Wild poliovirus transmission is endemic in only a handful of districts worldwide. The aim of the 2013-2018 Endgame Plan had been to be finished with this job by end 2018. This is not the case, and the Plan has to now be revised and extended through 2023.

This is an effort that cannot be sustained indefinitely: 31 years is long enough. It is resource intensive. It is intensive on the countries affected. It is intensive on donors. It is intensive on health services. It is intensive on communities. Most of all, it is intensive on those children and their families who bear the burden of this terrible disease, needlessly.

There is no reason why polio should persist anywhere in the world.

To succeed by 2023, all involved in this effort must find ways to excel in their roles. If this happens, success will follow.

This means stepping up the level of performance even further. It means using the proven tools of eradication and building blocks that have been established in parts of the world that have been free of polio for years. The vaccines, the cold chains, the networks of vaccinators, the surveillance capacity, the governance, policy, financing and oversight structures must be at peak levels of performance. There must be an unrelenting focus to tighten the management of the effort at all levels.

It also means looking for opportunities to innovate, using local knowledge and insights to overcome obstacles that in the past have seemed insurmountable. It means looking at new and different ways to reach children. It means really understanding the views of parents, and communities, who are unwilling to accept the vaccine and finding ways to address their concerns and come together with them. It means more effectively engaging with communities and better serving their needs than we have been doing thus far. Each person must dedicate themselves to one clear objective – to reach that very last child with polio vaccine.

Please commit to finding that very last child first, before the poliovirus does. Give the poliovirus nowhere to hide.

Whatever barrier to reaching that very last child, the programme has the expertise and experience to overcome it. Let everyone perfect what we know works. Let everyone free their mind to come up with new ideas and transformative solutions. We must all treat this as the public health emergency that it is.

As a global community, we have stood before where we stand today, with smallpox. The scourge of smallpox is gone, for which the world is a much better place. Let us make history again. It is time to finish the job of polio eradication now. The philosopher, poet and essayist Ralph Waldo Emerson said: “To leave the world a bit better, whether by a healthy child, a garden patch or a redeemed social condition, to know even one life has breathed easier because you have lived – this is to have succeeded.”

Eradicate polio, and make the world a better place for future generations.

Thank you.

Professor Alejandro Cravioto
   Chair of the Strategic Advisory Group of Experts on immunization (SAGE)

Sir Liam Donaldson
   Chair of the Independent Monitoring Board (IMB) of the Global Polio Eradication Initiative

Professor Helen Rees
   Chair of the Emergency Committee of the International Health Regulations (IHR) Regarding
      the International Spread of Poliovirus

Professor David Salisbury
   Chair of the Global Commission for the Certification of the Eradication of Poliomyelitis (GCC)

Featured Journal Content

Lancet Infectious Diseases
Apr 2019  Volume 19Number 4p339-448, e109-e147
http://www.thelancet.com/journals/laninf/issue/current

Editorial
Trust issues
The Lancet Infectious Diseases
In November, 2017, we published an Editorial on measles vaccination, calling for strong interventions to curb preventable diseases. 18 months later, how have things changed? As reported in a news story in this issue, 229,000 cases of measles were reported in 2018, and 98 countries reported an increase in cases compared with 2017. Measles is a global health crisis and it is getting worse. Although the reasons vary by country, mistrust and misplaced reluctance to vaccinate, largely related to unfounded fears over safety, are important contributing factors from the Philippines to France, from Ukraine to the USA. WHO has named vaccine hesitancy as one of the top ten threats to global health in 2019.

Lack of trust is also central to another of the world’s major health emergencies: the Ebola virus disease outbreak in DR Congo. The epidemic is focused in the northeast of the country, where conflict, political tensions, and social grievances have instilled fear and suspicion in much of the local population. 40% of new cases so far this year have been in people who died in the community (ie, they hadn’t been to a treatment centre), and a large proportion of cases, particularly in Katwa and Butembo, cannot be linked to any other patients, suggesting that unknown chains of transmission exist. If patients are wary of seeking proper care, and if contact tracing cannot be done, the outbreak will not be stopped.

Mistrust has also manifested with more direct and violent consequences in DR Congo. Médecins Sans Frontières (MSF) has reported dozens of attacks on its workers in the region. In February, two treatment centres were attacked and burned down, forcing MSF to suspend its activities in Katwa and Butembo. Joanne Liu, the president of MSF, has been quoted as describing the atmosphere towards the response as “toxic”.

The importance of community engagement to build trust was well recognised in the aftermath of the west Africa Ebola epidemic, but the difficulties of the DR Congo outbreak have led to the use of coercion against patients and their contacts, and a reliance on police and UN peacekeepers for security has further alienated the local population. MSF has criticised the use of coercion in DR Congo, and in an interview with STAT, Liu has said that “using police to force people into complying with health measures is not only unethical, it’s totally counterproductive“. WHO is taking a different tack: on March 9, it announced that it had sought further support from UN and local police forces to protect treatment centres, despite recognising the importance of “maintaining the neutrality of the response”.

As for trust in measles vaccination, a Danish study of more than 650,000 children once again confirms that measles, mumps, and rubella (MMR) vaccination is not associated with autism. But while the findings are welcome, the paper will not change the beliefs of anti-vaccination advocates. The safety of MMR was already well established before this study—a shortage of reliable scientific evidence is not the problem. And in countries such as the USA, the dangers of not vaccinating have been shown repeatedly, most recently in an outbreak of measles among mainly unvaccinated children in Washington and Oregon, as reported in our March issue. Rather, it is the abundance of misinformation and distrust of authority that must be addressed. Social media companies such as YouTube and Facebook have made changes to begin to stem the tide of misleading claims, but the impact of these initiatives remains to be seen.

An anti-vaxxer in California, USA, for example, is vastly different from someone potentially exposed to Ebola in rural DR Congo. Yet there are similarities in their mistrust. A belief that vaccines cause autism or that Ebola is a government ploy likely has as much to do with wider grievances and distrust of authority as with the specifics of the scientific evidence and education. Part of the problem is that a lack of faith in government, the health-care system, and pharmaceutical companies is not always irrational. In DR Congo, the postponement of elections in the regions affected by Ebola has been considered to be motivated more by politics than by public health (the region is a stronghold for opposition to the ruling party). The poverty and conflict in the region have long been neglected. In the USA, the country is plagued by prescription opioid misuse fuelled by aggressive pharmaceutical marketing, the people of Flint, MI, have been without safe drinking water for 3 years, and the most basic drugs are often unaffordable because of profit-driven health care. Little wonder that some individuals question the authorities’ desire to prioritise their wellbeing. It is impossible to build trust while at the same time abusing it.

Featured Journal Content

DRC – Ebola

WHO reaffirms commitment to Democratic Republic of the Congo as Ebola outbreak nears 1000 cases amid increased violence

WHO calls on international community to join urgent push to end outbreak
Statement
23 March 2019   Geneva/Brazzaville/Goma
As the Ebola outbreak in the Democratic Republic of the Congo (DRC) approaches 1000 cases amid increased violence, WHO reaffirmed its commitment both to ending the outbreak and working with the government and communities to build resilient health systems.

Since the outbreak was declared in August 2018 there have been 993 confirmed and probable cases and 621 deaths in North Kivu and Ituri provinces.

“We use words like ‘cases’ and ‘containment’ to be scientific, but behind every number is a person, a family and a community that is suffering,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This outbreak has gone on far too long. We owe it to the people of North Kivu to work with them in solidarity not only to end this outbreak as soon as possible, but to build the health systems that address the many other health threats they face on a daily basis.”

More than 96,000 people have been vaccinated against Ebola in DRC, along with health workers in Uganda and South Sudan. As of 21 March, 38 of 130 affected health areas have active transmission. More than 44 million border screenings have helped to slow the spread of Ebola in this highly mobile population. No cases have spread beyond North Kivu and Ituri provinces, and no cases have crossed international borders.

However, the risk of national and regional spread remains very high, especially when episodes of violence and instability impact the response.

“As we mourn the lives lost, we must also recognize that thousands of people have been protected from this terrifying disease,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “We are working in exceptionally challenging circumstances, but thanks to support from donors and the efforts of the Ministry of Health, WHO and partners, we have saved thousands of lives.”

WHO has more than 700 people in DRC and is working hard with partners to listen to the affected communities and address their concerns and give them greater ownership of the response, particularly in the current outbreak hotspots of Katwa and Butembo.

“The communities affected by this outbreak are already traumatized by conflict,” said Dr Tedros. ”Their fear of violence is now compounded by fear of Ebola. Community engagement takes time. There are no quick fixes. But we are learning and adapting to the evolving context every day.”

Despite the challenges, most communities accept response interventions. More than 90% of those eligible for vaccination accept it and agree to post-vaccination follow-up visits. Independent analysis of vaccination data indicate that the vaccine is protecting at least 95% of those who receive it in a timely manner. More than 80% of people also accept safe and dignified burials, a key to preventing onward transmission.

“Despite the increased frequency of attacks by armed groups, WHO will stay the course and will work with communities to end this outbreak together with the Ministry of Health and partners,” said Dr Tedros. “We need redoubled support from the international community, and a commitment to push together to bring this outbreak to an end.”

For the next 6 months, the combined financial need for all response partners is at least US$148 million. As of 19 March, US$ 74 million had been received.

“We count on donors to help close the funding gap so we can end this outbreak as soon as possible,” said Dr Tedros. “We will still be in DRC long after this outbreak has finished, working with the government and communities on the road to universal health coverage. We are committed to improving the health of the people of DRC now and in years to come.”

:: 34: Situation report on the Ebola outbreak in North Kivu  26 March 2019

:: Ebola virus disease – Democratic Republic of the Congo   28 March 2019

Emergencies

 
POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 20 March 2019
:: Dr Tedros Adhanom Ghebreyesus, WHO Director-General and Chair of the Polio Oversight Board, has issued a personal response to the extraordinary joint statement published in January by the Chairs of the main, independent, advisory and oversight committees of the GPEI.  The joint statement is an impassioned plea by the Chairs of the Strategic Advisory Group of Experts on immunization (SAGE), the Independent Monitoring Board, the Emergency Committee of the International Health Regulations (IHR) Regarding International Spread of Poliovirus and the Global Commission for the Certification of the Eradication of Poliomyelitis (GCC) – the Chairs urged everyone involved in the GPEI to ensure polio will finally be assigned to the history books by 2023. [see above]
:: On 27 March 2019, the WHO’s Southeast Asia Region marked five years since being declared wild polio-free, with the last case in the Region detected in India on 13 January 2011. The five-year anniversary of SEARO certification celebrated success in India and across countries of the region, showcasing how countries have used the skills, knowledge and infrastructure built up by the polio programme after eradication and highlight lessons learned from the Region that are now being applied in other parts of the world.

 Summary of new viruses this week:
:: Pakistan – two wild poliovirus type 1 (WPV-1) cases and 15 WPV1-positive environmental samples;
:: Nigeria— two circulating vaccine-derived poliovirus type 2 (cVDPV2) cases, one cVDPV2-positive environmental.

::::::
::::::

 Editor’s Note:
WHO has posted a refreshed emergencies page which presents an updated listing of Grade 3,2,1 emergencies as below.

WHO Grade 3 Emergencies  [to 30 Mar 2019]
Democratic Republic of the Congo
:: 34: Situation report on the Ebola outbreak in North Kivu  26 March 2019
:: Ebola virus disease – Democratic Republic of the Congo   28 March 2019

Syrian Arab Republic
:: Health situation – Al-Hol camp  16 March 2019

South Sudan
::  Kawthar defeats tuberculosis: improving access to diagnosis and treatment in rural areas in Syria  27 March 2019

Myanmar
:: WHO appeals for international community support; warns of grave health risks to Rohingya refugees in rainy season
Dhaka, 29 March 2018 – With a grossly underfunded health sector grappling to meet the needs of 1.3 million Rohingyas in Bangladesh’s Cox’s Bazar, the World Health Organization has appealed to the international community to contribute generously to enable appropriate and timely health services to this highly vulnerable population, now facing grave risks to their lives and health in view of the coming rainy season…

Yemen
:: Two years since world’s largest outbreak of acute watery diarrhoea and cholera, Yemen witnessing another sharp increase in reported cases with number of deaths continuing to increase
Muscat/Amman/Cairo, 26 March 2019 – “In Yemen, since the beginning of the year until 17 March, nearly 109 000 cases of severe acute watery diarrhoea and suspected cholera were reported with 190 total associated deaths since January. Nearly one third of the reported cases are children under the age of 5. This comes 2 years since Yemen witnessed the world’s largest outbreak when more than 1 million cases were reported.
“We fear that the number of suspected cholera cases will continue to increase with the early arrival of the rainy season and as basic services, including lifesaving water systems and networks, have collapsed. The situation is exacerbated by the poor status of sewage disposal systems, the use of contaminated water for agriculture, unreliable electricity to store food and    the displacement of families as they flee escalating violence, especially in Hudaydah and Tai’z.
“Our teams in Yemen are working day and night with a wide network of local partners to respond and stop the further spread and transmission of disease. Focusing on 147 priority districts, additional health, water, hygiene and sanitation supplies are being mobilized. Rapid response teams have been deployed. A total of 413 diarrhoea treatment centres and oral rehydration centres are operational in all 147 priority districts. Partners are repairing water and sanitation systems. In the past weeks, we scaled up chlorination activities to disinfect water in 95 priority districts and provided fuel and spare parts to keep going water supply and sanitation networks. A round of oral cholera vaccine campaign reached over 400 000 people in several districts. Meanwhile, community-based awareness-raising efforts reached 600 000 people in house-to-house campaigns since early 2019 to provide families with information on hygiene practices and improve the reporting of symptoms and seeking of treatment…

Bangladesh – Rohingya crisis – No new digest announcements identified  
Nigeria – No new digest announcements identified  
Somalia – No new digest announcements identified

::::::

 WHO Grade 2 Emergencies  [to 30 Mar 2019]
occupied Palestinian territory 
:: WHO strongly condemns killing of health worker in the West Bank, March 2019
The World Health Organization (WHO) strongly condemns the killing of Sajed Mazher, a first responder working with the Palestinian Medical Relief Society in the West Bank, occupied Palestinian territory…

Brazil (in Portugese) – No new digest announcements identified
Cameroon  – No new digest announcements identified
Central African Republic  – No new digest announcements identified
Ethiopia – No new digest announcements identified
Hurricane Irma and Maria in the Caribbean – No new digest announcements identified
Iraq – No new digest announcements identified  
Libya – No new digest announcements identified
MERS-CoV – No new digest announcements identified
Niger – No new digest announcements identified
Sao Tome and Principe Necrotizing Cellulitis (2017) – No new digest announcements identified
Sudan – No new digest announcements identified
Ukraine – No new digest announcements identified
Zimbabwe – No new digest announcements identified

::::::

WHO Grade 1 Emergencies  [to 30 Mar 2019]
Afghanistan
Chad
Indonesia – Sulawesi earthquake 2018
Kenya
Lao People’s Democratic Republic
Mali
Namibia – viral hepatitis
Peru
Philippines – Tyhpoon Mangkhut
Tanzania

::::::

WHO AFRO – Outbreaks and Emergencies Bulletin – Week 12/2019
Week 12: 18- 24 March 2019
The WHO Health Emergencies Programme is currently monitoring 65 events in the region. This week’s edition covers key new and ongoing events, including:
:: Cyclone in Mozambique and Zimbabwe
:: Ebola virus disease in Democratic Republic of the Congo
:: Humanitarian crisis in Mali
:: Humanitarian crisis in Central African Republic 

::::::

::::::

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Yemen
:: Yemen Humanitarian Update Covering 7 – 21 March 2019 | Issue …

Syrian Arab Republic   – No new digest announcements identified

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Ethiopia 
:: Ethiopia Humanitarian Bulletin Issue #5 | 4-17 March 2019

Somalia  – No new digest announcements identified

WHO & Regional Offices [to 30 Mar 2019]

27 March 2019 | News Release
Diseases cost African region $2.4 trillion per year
WHO launches an investment case to achieve SDGs and universal health coverage in Africa 
Praia, Cabo Verde, 27 March 2019 – The World Health Organization (WHO) estimates that nearly 630 million years of healthy life were lost in 2015 due to the diseases afflicting the population across its 47 Member States in Africa, now amounting to a loss of more than 2.4 trillion international dollars ($) from the region’s gross domestic product value annually.
Noncommunicable diseases have overtaken infectious diseases as the largest drain on productivity, accounting for 37 per cent of the disease burden. Other culprits for lost healthy years are communicable and parasitic diseases; maternal, neonatal and nutrition-related conditions; and injuries.
Around 47%, or $ 796 billion, of this lost productivity value could be avoided in 2030 if the Sustainable Development Goals related to these health conditions are achieved, WHO found.
“Four years into the implementation of countries’ efforts towards achieving UHC, current average expenditure on health in the Region falls short of this expectation,” the WHO Regional Director for Africa, Dr Matshidiso Moeti, writes in the foreword to A Heavy Burden: The Productivity Cost of Illness in Africa, which was launched during the second WHO Africa Health Forum this week in Cabo Verde.
As a target of Sustainable Development Goal 3, universal health coverage would require countries in the WHO African Region to spend, on average, at least $ 271 per capita per year on health, or 7.5% of the region’s gross domestic product…

26 March 2019 | News Release
Yemen witnessing sharp increase in reported cases of acute watery diarrhoea and cholera

22 March 2019   Statement
WHO reaffirms commitment to Democratic Republic of the Congo as Ebola outbreak nears 1000 cases amid increased violence

WHO calls on international community to join urgent push to end outbreak

[See Ebola above for detail]

::::::

 
Weekly Epidemiological Record, 29 March 2019, vol. 94, 13 (pp. 161–168)
:: Retrospective detection of Zika virus transmission in Paraguay – January to December 2016
:: Addendum to the Recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season

WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region AFRO
:: In Madagascar, mothers show grit to protect their children as government, partners battle measles epidemic  29 March 2019
:: Diseases cost the African Region $2.4 trillion a year, says WHO  27 March 2019
:: WHO Mobilizes Urban-based Congolese Refugees in Uganda for Ebola action  26 March 2019
:: WHO reaffirms commitment to Democratic Republic of the Congo as Ebola outbreak nears 1000 cases amid increased violence  24 March 2019
 
 
WHO Region of the Americas PAHO
– No new digest announcements identified.
 
 
WHO South-East Asia Region SEARO
:: Marking five years of polio-free certification, WHO South-East Asia Region uses polio legacy to enhance overall immunization   SEAR/PR/1708
New Delhi, 27 March 2019: On this day in 2014, WHO South-East Asia Region was certified polio-free, proving wrong many public health experts who believed that the Region, which accounts for one-fourth of the global population, would be the last bastion for polio eradication. Five years on, the Region not only continues to maintain its polio-free status but is demonstrating how the polio legacy can effectively strengthen overall immunization and other programs…
 
 
WHO European Region EURO
:: Improving TB patient care in the Russian Federation with video-observed treatment 28-03-2019
 
 
WHO Eastern Mediterranean Region EMRO
:: WHO strongly condemns killing of health worker in the West Bank  27 March 2019
:: Yemen witnessing sharp increase in reported cases of acute watery diarrhoea and cholera
27 March 2019
:: Improving health outcomes for people with TB in Syria  27 March 2019
:: Polio immunization campaign in Somalia aims to leave no child under 5 behind  26 March 2019
:: WHO to release Arabic version of package on health system response to violence against women and girls
27 March 2019 ‒ As part of its effort to address violence against women and girls, the WHO Regional Office for the Eastern Mediterranean is launching an Arabic version of the WHO package on health system response to violence against women and girls. In releasing this evidence-based guidance, WHO seeks to ensure that preventing and responding to violence against women and…

WHO Western Pacific Region
:: Immunization gaps threaten gains on measles
29 March 2019   News Release  Manila, Philippines
Measles outbreaks in the World Health Organization (WHO) Western Pacific Region are putting babies, children and young people at risk and threatening progress towards wiping out the disease.
The Region had historically low levels of measles cases and no major outbreaks in 2017. This landmark decline was achieved through steady efforts to vaccinate all children against measles, but last year, measles cases in the Region increased by 250%, and more than two-thirds of cases were in the Philippines. So far this year, the Philippines has reported 23 000 cases with 333 deaths — already more than all of last year. Tragically, most of the cases were among children under 5 years old.
Measles can cause debilitating complications, including encephalitis, severe diarrhoea and dehydration, pneumonia, ear infections and permanent vision loss.
“In recent months, we’ve seen how swiftly and easily measles can make a comeback in communities where not enough children have been immunized,” said WHO Regional Director for the Western Pacific Takeshi Kasai…
 

CDC/ACIP [to 30 Mar 2019]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News
CDC: Artesunate Now First-Line Treatment for Severe Malaria in the United States
Thursday, March 28, 2019
Only FDA-approved antimalarial drug, quinidine, has been discontinued

Ebola outbreak in eastern Democratic Republic of Congo tops 1,000 cases
Monday, March 25, 2019
CDC remains committed to bringing outbreak to an end
As of March 24, 2019, public health officials have documented that the Ebola outbreak in eastern Democratic Republic of Congo (DRC) has surpassed 1,000 cases; the current total number of confirmed and probable cases is 1009, including 625 deaths and 318 survivors. The outbreak is the largest in DRC’s history and the second largest outbreak recorded of Ebola ever (after the 2014-2016 outbreak in West Africa).
“This is a disappointing milestone. This remains a highly complex Ebola outbreak with active transmission in 13 of the 21 affected health zones,” said CDC Director Robert R. Redfield, M.D. “Despite this, CDC will continue to work 24/7 with our partners in DRC, in DRC’s neighboring countries, and around the world to prevent the spread of Ebola and bring this outbreak to an end.”…

MMWR News Synopsis for Friday, March 29, 2019
Enterovirus D68-Associated Acute Respiratory Illness — United States, July–October, 2017 and 2018
CDC recently established surveillance of children seen in emergency departments or hospitalized for acute respiratory illness at seven U.S. medical centers. Substantially more children tested positive for Enterovirus D68 (EV-D68) in the 2018 season compared with 2017.
EV-D68 is one of many known enteroviruses. It can cause mild to severe respiratory illness or no symptoms at all. EV-D68 infections typically peak during late summer and early fall in the United States. National reporting of EV-D68 is voluntary. To better understand annual trends of EV-D68 illness, seven U.S. medical centers, participating in CDC’s New Vaccine Surveillance Network (NVSN), are conducting surveillance among children either seen in emergency departments or hospitalized for acute respiratory illness (ARI). From July 1 – October 31, 2018, EV-D68 infections were detected in 358 children with ARI, compared with two during the same period in 2017. Continued active surveillance of EV-D68-associated ARI is key to understanding the circulation and seasonality of EV-D68.

Africa CDC   [to 30 Mar 2019]
https://au.int/en/africacdc
March 29, 2018
First Progress Report of the Chairperson of the Commission on the Africa Center for Disease Control
11 pages – PDF: https://au.int/sites/default/files/documents/34074-doc-auc.report.africa.cdc_.prc_.29.03.pdf
[Excerpt]
… 22. At this time, Africa CDC’s fulfilment of its mandate is hampered by small numbers of permanent staff supporting administrative functions at the secretariat. The majority of Africa CDC support currently comes from seconded or contracted staff. Efforts are underway to address these challenges.

23. Africa CDC has succeeded in developing bilateral partnerships with several nations outside the African continent. Within AU Member States, only the Republic of Kenya has provided a voluntary contribution of USD 1 million to support the Africa CDC. Sustainable support among Member States is critical for sustainable growth and expansion of Africa CDC.

24. Africa CDC is pursuing a mechanism for sustainable financing through businesses, the private sector, and African philanthropy. The Africa CDC private sector and philanthropy engagement strategy has been developed and presented to the Africa CDC Governing Board. This strategy has been aligned and coordinated with plans for Africa CDC Foundation. A priority
focus has been on identifying African companies dealing in telecommunications and other sectors. Finally, Africa CDC is engaging African philanthropists who have given historical support to the African health agenda.

V. OBSERVATIONS
25. Africa CDC has recorded notable achievements to mark its first year of existence. It is successfully fulfilling the mandate it received from the Assembly, even while it continually expands and develops new avenues for strengthening public health capacity on the African continent.

26. Member States have demonstrated their continued support and enthusiasm for Africa CDC by robust participation to produce various framework documents that will guide their public health activities at the national level. These framework documents include a strategy to introduce event-based surveillance at the continental, regional, and national levels; a framework to establish a national public health institute in every Member State; a framework
to address the threat of antimicrobial resistance.

27. In its inaugural year, Africa CDC responded to ten public health events in Member States with a limited technical staff (only ten epidemiologists are currently seconded to Africa CDC). These same epidemiologists also provide day-to-day administrative and management support to operations at the Africa CDC secretariat.

28. While three of the Africa CDC RCC have had successful political launches, they require substantial human resource support to ensure that the technical aspects of Africa CDC’s strategic plan is successfully implemented at the regional level. Without each RCC, Africa CDC has limited ability to encourage public health coordination among Member States. It is crucial to ensure that the West Africa and North Africa are launched in 2018. I look forward to nominating a North African technical public health institution motivated and equipped to provide support to the entire region, cognizant of the diverse array of needs represented in North Africa.

29. I encourage Member States to participate actively in the public health platform established by the Regional Collaborating Centres. Laboratory networks, coordination during public health events, and information exchange are critical elements of the RCC mandate.
End

China CDC 
http://www.chinacdc.cn/en/

New website launched…no “news” or “announcements” page identified. Link to National Health Commission of the People’s Republic of China not responding at inquiry [30 Mar 2019]

Announcements

Paul G. Allen Frontiers Group    [to 30 Mar 2019]
https://www.alleninstitute.org/news-press/
No new digest content identified.
 
 
BMGF – Gates Foundation  [to 30 Mar 2019]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.
 
 
Bill & Melinda Gates Medical Research Institute    [to 30 Mar 2019]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
 
 
CARB-X   [to 30 Mar 2019]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
 
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 30 Mar 2019]
http://cepi.net/
29 Mar 2019
The woman who helped to stop an Ebola epidemic in Nigeria
By Niniola Soleye
In 2014-2016, West Africa experienced the largest Ebola outbreak to date. Thanks to the heroic work of Dr Ameyo Stella Adadevoh and others, Nigeria steered clear of what could have been a very deadly outbreak of the disease. Tragically Dr Adadevoh lost her life to Ebola, but her legacy lives on today through the Dr Ameyo Stella Adadevoh Health Trust…

29 Mar 2019 – Comment
You can’t beat epidemics without equitable access to vaccines
By Richard Hatchett, CEPI CEO
We’re developing vaccines against emerging infectious diseases. Getting them to the people who need them, when they need them, regardless of ability to pay, is not just important for access, it’s the only way to beat epidemic… CEPI is 100% committed to equitable access. This commitment drives every aspect of our work and is key to our success as a global health organisation…
 
 
EDCTP [to 30 Mar 2019]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.
 
 
Emory Vaccine Center [to 30 Mar 2019]
http://www.vaccines.emory.edu/
No new digest content identified.
 
 
European Medicines Agency  [to 30 Mar 2019]
http://www.ema.europa.eu/ema/
News and press releases
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 March 2019
CHMP, 29/03/2019
 
 
European Vaccine Initiative  [to 30 Mar 2019]
http://www.euvaccine.eu/news-events
Latest news
GHIT supports further development of a new asexual blood-stage malaria vaccine candidate
29 March 2019
Goal of new project is to further advance the development of a new vaccine candidate based on the PfRipr5 protein of…
 
 
FDA [to 30 Mar 2019]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
March 29, 2019 –
Statement by FDA Commissioner Scott Gottlieb, M.D., Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, M.D. and Director of FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D. on Expanded Access –Looking Forward
…But sometimes, even in circumstances where the availability of a medicine through EA would appropriately balance these considerations, such access is not available. This is often true when it comes to the ability of patients to continue to use a promising medicine after the completion of a clinical trial.
We are writing to encourage sponsors to offer EA in such circumstances, when continued access to a promising medicine at the completion of a clinical trial would be appropriate under the EA programs.
Although we often focus on EA as providing access to patients who cannot enter clinical trials, EA can also be considered as a mechanism for those who have participated in a trial in order to allow them to continue receiving a drug that may have provided benefit. At the end of a trial, sponsors may continue to provide treatment to participating patients through an extension study to gather additional rigorous information that’s needed to support the subsequent marketing application. Alternatively, if the purpose is primarily to provide the drug to patients who continue to need it, an EA program may be used for either moderately sized populations (intermediate EA) or large size populations (treatment EA), often when most studies in support of approval have been completed. As another option, a sponsor could authorize a patient’s own physician to obtain a single patient EA investigational new drug (IND) application…
 
 

Fondation Merieux [to 30 Mar 2019]
http://www.fondation-merieux.org/
No new digest content identified.

 
Gavi [to 30 Mar 2019]
https://www.gavi.org/
Latest News
27 March 2019
Leadership training for supply chain managers expands to five African countries
Over 22 private sector partners will support the innovative training and mentorship programme.
Nairobi/Accra,– The Strategic Training Executive Programme (STEP) for supply chain managers is expanding to five African countries, including Kenya, Ghana, Mozambique, Madagascar and the Democratic Republic of the Congo (DRC), thanks to financial and in-kind support from the International Federation of Pharmaceutical Wholesalers (IFPW). The expansion of STEP is the result of significant country demand for stronger capacity in supply chain management. By the end of 2020, Gavi and IFPW expect more than 600 immunisation supply chain leaders to graduate from STEP programmes across Africa and Asia.
“STEP has become an essential component of Gavi’s support to strengthen supply chain management in low-income countries,” said Gavi Deputy CEO Anuradha Gupta. “With country demand increasing, what began as an effort to foster regional supply chain expertise in East Africa has extended well beyond this goal. Our continued partnership with IFPW allows even more Gavi-supported countries to benefit from improved management of health supply chains,” she added…
 
 
GHIT Fund   [to 30 Mar 2019]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical

March 28, 2019
GHIT Fund Announces Appointment of Catherine Ohura as New CEO and Executive Director
The Global Health Innovative Technology Fund (GHIT) today announced the appointment of Catherine Ohura as the organization’s new CEO and Executive Director. Ohura brings depth and breadth of expertise and invaluable experience working for R&D and Commercial functions. In the R&D function, Ohura worked in clinical operations, regulatory affairs, quality assurance, project management, finance/resource management, portfolio management, and governance creation/management…

March 28, 2019
GHIT Fund Announces New Investments: A Total of 2.86 Billion Yen in Drug for Schistosomiasis, Dengue, Malaria and Tuberculosis, Vaccines for Leishmaniasis and Malaria, and Diagnostics for Tuberculosis
The Global Health Innovative Technology (GHIT) Fund announced today a total of 2.86 billion yen (US$25.8 million*) to support 10 partnerships to develop new lifesaving drugs, vaccines, and diagnostics for malaria, tuberculosis, dengue, leishmaniasis, and schistosomiasis. This includes three new projects and seven that will receive continued funding. (Appendix 1)
“We are thrilled to see our portfolio continue to advance and accelerate, to expand and evolve. This marks now a total of 17 billion yen (US$153 million*) invested in over 80 global product development partnerships aimed to leverage Japanese science and pharmaceutical capabilities through global partnership. Side by side with our partners, GHIT continues to drive ahead looking to deliver lifesaving tools to save millions of lives.” said, said BT Slingsby, the CEO of GHIT.
Currently, there are 50 ongoing projects including 27 discovery, 15 preclinical, and eight clinical trials in the GHIT portfolio…

Global Fund [to 30 Mar 2019]
https://www.theglobalfund.org/en/news/
News
No new digest content identified.

Hilleman Laboratories [to 30 Mar 2019]
http://www.hillemanlabs.org/
No new digest content identified.

Human Vaccines Project [to 30 Mar 2019]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.

IAVI  [to 30 Mar 2019]
https://www.iavi.org/newsroom
March 27, 2019
IAVI Announces First-in-Human Clinical Trial of Native-like HIV Envelope Vaccine Candidate
NEW YORK — MARCH 27, 2019 — The International AIDS Vaccine Initiative (IAVI) announced the start of a Phase I clinical trial (IAVI W001) to test a novel HIV vaccine candidate, BG505 SOSIP.664 gp140. The aim of the trial is to assess the safety of the candidate and to determine if vaccination induces the human immune system to produce proteins known as neutralizing antibodies (NAbs).
Mark Feinberg, M.D., Ph.D., president and CEO of IAVI, said, “This trial is unique because it represents the fruition of decades of scientific research to engineer this promising vaccine candidate. Much important work was done in the late 1990s and early 2000s to attempt to stabilize the HIV envelope protein in its native configuration, but this difficult work took several more years to achieve.”
BG505 SOSIP.664 gp140 is based on the HIV envelope protein (Env), which is shaped like a three-pronged spike. This configuration, known as a trimer, is a target for antibodies produced by the human immune system after infection. Some of these antibodies are able to block viral entry into cells.
The BG505 SOSIP.664 gp140 trimer was engineered by a team directed by John P. Moore, Ph.D., at the Weill Cornell Medical College, Rogier Sanders, Ph.D., now at the University of Amsterdam Academic Medical Center, and Andrew B. Ward, Ph.D., and Ian A. Wilson, D.Phil., at Scripps Research. The outcome of their work was an important advance in stabilizing the highly fragile Env protein in a native-like configuration.
This is one of the first clinical trials of a native-like Env trimer, and the first time that this particular trimer is being evaluated in humans…

IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.

IFRC   [to 30 Mar 2019]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Americas, Venezuela
IFRC to bring humanitarian aid into Venezuela
The President of the International Federation of Red Cross and Red Crescent Societies (IFRC) has announced that IFRC will have unhindered access to bring humanitarian aid into Venezuela to support a major scale up of medical care and other assistance by the Venezuela Red Cross.
29 March 2019

Afghanistan, Asia Pacific
Afghanistan: Ten million Afghans face severe hardship after extreme weather
Ten million people in Afghanistan – more than a quarter of its population – face severe acute food insecurity and need urgent help after floods and drought, say the Afghan Red Crescent Society and the International Federation of Red Cross and Red Crescent Societies (IFRC).
28 March 2019

Africa, Mozambique
Mozambique: Red Cross races to stop new disaster following confirmation of first cholera cases
News that the first cases of deadly cholera have been confirmed in Mozambique has accelerated Red Cross and Red Crescent disease prevention activities in the vulnerable communities that have been devastated by Cyclone Idai. Jamie LeSueur, head of operations with the International Federation of Red Cross and Red Crescent Societies (IFRC) in Beira, said: “We will all have to move extremely fast to stop these isolated cases from becoming another major disaster within the ongoing crisis of Cyclone Idai.
27 March 2019

Mozambique
Mozambique: “Speed, quality and scale of response critical to preventing disease outbreaks,” says IFRC Secretary General
Geneva/Nairobi/Beira, 25 March 2019 – The Red Cross and Red Crescent network is speeding up efforts to prevent disease outbreaks in the aftermath of Cyclone Idai, with the arrival today of an Emergency Response Unit that will provide sanitation for 20,000 people every day. Two emergency field hospitals will follow. “After a disaster of this magnitude, the speed, quality, and scale of our response is critical to to stop the risk of waterborne disease outbreaks like cholera,” said the Secretary General of the International Federation of Red Cross and Red Crescent Societies (IFRC), Elhadj As Sy, at a media briefing at the United Nations in Geneva today. “As flood waters recede, hundreds of thousands of people still lack water, shelter and health care. We now see even more clearly the real consequences of this disaster.”
25 March 2019

Asia Pacific, Indonesia
Indonesia: Six months after Sulawesi triple disaster, survivors face slow and complex recovery
Palu/Kuala Lumpur, 25 March 2019 – Six months after Sulawesi was hit by a powerful and shallow earthquake, tsunami and liquefaction, survivors face a painfully slow and complex recovery. On 28 September 2018, a series of strong earthquakes struck Centr …
25 March 2019
 
 
IVAC [to 30 Mar 2019]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
No new digest content identified.

IVI [to 30 Mar 2019]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

JEE Alliance [to 30 Mar 2019]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 
MSF/Médecins Sans Frontières  [to 30 Mar 2019]
http://www.msf.org/
Selected News; Project Updates, Reports [as presented on website]
Cyclone Idai & Southern Africa flooding
The first six days after Cyclone Idai in Zimbabwe
Voices from the Field 29 Mar 2019

Cyclone Idai & Southern Africa flooding
Malawi: “This time, the flooding has destroyed houses, not lives”
Voices from the Field 29 Mar 2019

Cyclone Idai & Southern Africa flooding
MSF emergency response to Cyclone Idai and flooding
Crisis Update 29 Mar 2019

Palestine
March of Return protestors abandoned after year of suffering
Project Update 28 Mar 2019

Cyclone Idai & Southern Africa flooding
Mozambique declares cholera cases in Beira in wake of Cyclone Idai
Project Update 28 Mar 2019

Cyclone Idai & Southern Africa flooding
Mozambique flooding and response: both enormous in scale
Project Update 27 Mar 2019

Venezuela
MSF’s work across Venezuela
Interview 27 Mar 2019

Yemen
MSF treats exponential increase in cholera cases since start of 2…
Press Release 27 Mar 2019

Central American Migration
People fleeing put at risk through dangerous government migrati…
Voices from the Field 26 Mar 2019

Iraq
The aftermath of the conflict in Hawija: “My only hope is to get b…
Project Update 26 Mar 2019

DRC 2018 Ebola outbreaks
Crisis update – March 2019
Crisis Update 25 Mar 2019
 
 
NIH  [to 30 Mar 2019]
http://www.nih.gov/news-events/news-releases
March 28, 2019
Harnessing T-cell “stemness” could enhance cancer immunotherapy
— Study sheds light on one way tumors may continue to grow despite the presence of cancer-killing immune cells.
 
 
PATH [to 30 Mar 2019]
https://www.path.org/media-center/
No new digest content identified.
 
 
Sabin Vaccine Institute [to 30 Mar 2019]
http://www.sabin.org/updates/pressreleases
No new digest content identified.
 
 
UNAIDS [to 30 Mar 2019]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements

27 March 2019
Liberia’s catch-up plan takes shape

27 March 2019
UN and AU working together for sustainable development

26 March 2019
Modelling the next set of HIV data

25 March 2019
Only half of HIV-exposed babies are tested for HIV
 
 
UNICEF  [to 30 Mar 2019]
https://www.unicef.org/media/press-releases
Selected Press Releases/Reports/Statements

Press release
Participation in sport can improve children’s learning and skills development, new Barça Foundation and UNICEF report finds
The report launches today at an international consultation on sport for development for children at the FC Barcelona Auditorium
28/03/2019

Press release
Cyclone Idai: More than 1.5 million children urgently need assistance across Mozambique, Malawi and Zimbabwe – UNICEF
UN children’s agency launches US$122 million humanitarian appeal amidst worst disaster to hit southern Africa in decades
27/03/2019

Statement
Two years since world’s largest outbreak of Acute Watery Diarrhea and Cholera, Yemen witnessing another sharp increase in reported cases with number of deaths continuing to increase
Statement by Geert Cappelaere, UNICEF Regional Director in the Middle East and North Africa and Dr Ahmed Al Mandhari, WHO Regional Director for the Eastern Mediterranean
26/03/2019

Press release
Participation in sport can improve children’s learning and skills development, new Barça Foundation and UNICEF report finds26/03/2019

Press release
Participation in sport can improve children’s learning and skills development, new Barça Foundation and UNICEF report finds26/03/2019

Press release
Participation in sport can improve children’s learning and skills development, new Barça Foundation and UNICEF report finds26/03/2019

Statement
Statement by UNICEF Executive Director Henrietta Fore on village attack in Mali
24/03/2019

Press release
Participation in sport can improve children’s learning and skills development, new Barça Foundation and UNICEF report findsUNICEF Executive Director Henrietta Fore wraps up visit to affected area of Beira one week after Cyclone hit
23/03/2019
 
 
Vaccine Confidence Project  [to 30 Mar 2019]
http://www.vaccineconfidence.org/
No new digest content identified.
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 30 Mar 2019]
http://www.chop.edu/centers-programs/vaccine-education-center
March 2019
Newsletter
Announcements: Webinar update and reminder, autism Q&A revised, vaccine safety issues 
 
 
Wellcome Trust  [to 30 Mar 2019]
https://wellcome.ac.uk/news
Opinion | 29 March 2019
We want to champion new conversations with the public about health
by Lucy McDowell
Wellcome wants to promote new practices in public dialogue to involve a broader, more diverse range of people in discussions about health challenges and how we face them

The Wistar Institute [to 30 Mar 2019]
https://www.wistar.org/news/press-releases
No new digest content identified.

World Organisation for Animal Health (OIE) [to 30 Mar 2019]
http://www.oie.int/en/for-the-media/press-releases/2019/
No new digest content identified.

::::::

BIO [to 30 Mar 2019]
https://www.bio.org/insights/press-release
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 30 Mar 2019]
http://www.dcvmn.org/
No new digest content identified.

IFPMA [to 30 Mar 2019]
http://www.ifpma.org/resources/news-releases/
No new digest content identified.

PhRMA [to 30 Mar 2019]
http://www.phrma.org/press-room
No new digest content identified.

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org